What type of targeted drug does Revumenib belong to for the treatment of leukemia?

Revumenib is a new type of small molecule targeted drug specifically targeting leukemia and other related tumors driven by the NUT fusion protein (NUTM1 fusion gene). The drug inhibits key members of the BET protein family and blocks abnormal gene transcription mediated by NUT fusion proteins, thereby inhibiting the proliferation and survival of tumor cells and showing strong anti-tumor activity.

NUTFusion protein-positive leukemia is a rare subtype of acute leukemia with poor prognosis, and traditional chemotherapy has limited effect. As a BET inhibitor, Revimenib has shown significant efficacy against this subtype of leukemia in clinical trials, providing a new treatment option for this type of patients. It can selectively target tumor driving factors and reduce damage to normal cells.

Different from common leukemia-targeted drugs such as tyrosine kinase inhibitors (TKI), Revimenib is an epigenetic regulatory drug that regulates gene expression by inhibiting BET proteins and blocks oncogenic signals of tumor cells. Its unique mechanism of action makes it valuable in the treatment of specific molecular subtypes of leukemia, especially in patients who have failed conventional treatments.

Currently, Revimenib is in the clinical trial stage, and multiple studies have shown its promising efficacy in patients with NUT fusion protein-positive leukemia. With the deepening of research, this drug is expected to become an important breakthrough in the field of precision treatment. In the future, Revemenib may be expanded to the treatment of other tumor types, bringing good news to more patients.

Reference materials:https://www.drugs.com/